SAN DIEGO, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company reimagining therapeutic delivery, today announced the signing of financing agreements with its existing convertible notes holders. "We appreciate the continued commitment of our existing noteholders, who have agreed to an additional investment in Biora that we expect will fund us to important milestones, including anticipated partnering with large pharma," said Eric d'Esparbes, Chief Financial Officer of Biora Therapeutics. "Active pharma collaborator interest in our BioJet™ platform, and recent promising clinical trial results from our NaviCap™ platform, are drivers for this commitment." About Biora TherapeuticsBiora Therapeutics is a clinical-stage biotech developing two smart pill-based therapeutics platforms: the NaviCap™ platform for colon-targeted treatment of IBD, designed to improve patient outcomes through treatment at the site of disease in the gastrointestinal tract, and the BioJet™ platform for oral delivery of large molecules, designed to replace injection with needle-free, oral delivery for better management of chronic diseases. For more information, visit bioratherapeutics.com or follow the company on LinkedIn or X. About the NaviCap™ Targeted Oral Delivery Platform and BT-600Biora's NaviCap™ platform for colon-targeted treatment of inflammatory bowel disease (IBD) is designed to improve patient outcomes by increasing therapeutic activity in tissue at the site of disease while also reducing systemic uptake to improve safety. BT-600 is a drug/device combination of the NaviCap™ ...